Suvorexant
Breast Cancer
Medical University of South CarolinaSmall moleculePhase 4 / ApprovedActive
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 59/ 100
Competitive context
890 Active assets in the Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lapatinib University of New Mexico | Phase 3 | BBB |
Darolutamide Vandana Abramson | Phase 2 | BBB |
Trastuzumab Duocarmazine Byondis B.V. | Phase 3 | BB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BB |
Palbociclib Hoffmann-La Roche | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Suvorexant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →